Hereditary Angioedema Therapeutics Global Market Report 2025

Global Hereditary Angioedema Therapeutics Market Report 2024

Hereditary Angioedema Therapeutics Global Market Report 2025 – By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels), By Application (Prophylaxis, On-demand) – Market Size, Trends, And Global Forecast 2025-2034

Name: Hereditary Angioedema Therapeutics Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Hereditary Angioedema Therapeutics Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Hereditary Angioedema Therapeutics Global Market Report 2025

Proud Members Of

Hereditary Angioedema Therapeutics Market Definition

Hereditary angioedema (HAE) therapeutics refers to therapy for an autosomal dominant condition brought on by a deficiency in or malfunction of the C1-inhibitor protein. Hereditary angioedema symptoms include angioedema-related upper airway, cutaneous, and, or gastrointestinal complaints.

The main drug classes of hereditary angioedema therapeutics are C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, kallikrein inhibitor, others. C1 Esterase Inhibitor refers to a protein called that is present in the fluid portion of blood and it regulates the complement system's protein C1, which goes by the name of C1. The therapeutics are administered through intravenous, Subcutaneous, and oral, distributed via Hospital Pharmacy, retail pharmacy, and others. The application of hereditary angioedema therapeutics include prophylaxis and on-demand.

Hereditary Angioedema Therapeutics Market Segmentation

The hereditary angioedema therapeutics market covered in this report is segmented –

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

2) By Route of Administration: Intravenous, Subcutaneous, Oral

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

4) By Application: Prophylaxis, On-demand

Subsegments:

1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant

2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant

3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab

4) By Other Drug Classes: Emerging Therapies

Hereditary Angioedema Therapeutics Market Size and growth rate 2025 to 2029: Graph

Hereditary Angioedema Therapeutics Market Size 2025 And Growth Rate

The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from$6.68 billion in 2024 to $7.84 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals

Hereditary Angioedema Therapeutics Market Growth Forecast

The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $16.11 billion in 2029 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics.

Book your 30 minutes free consultation with our research experts

Hereditary Angioedema Therapeutics Market Driver: Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market

The rising prevalence of hereditary angioedema is expected to propel the growth of the hereditary angioedema market going forward. Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling of the skin and mucous membranes. The swelling is caused by excess fluid build-up (EDEMA) and can occur anywhere in the body, including the hands and feet, face, intestines, and airways. For Instance, in June 2022, according to Rare Disease Advisor, an online resource company that provides health care professionals, globally, 1 in every 50,000 persons suffer from hereditary angioedema with prevalence estimates ranging from 1:10,000 to 1:150,000. HAE episodes cause 15,000 to 30,000 emergency room visits each year in the US. 5.8% of cases of HAE had an average time to diagnosis of 0 to 6 months, whereas 5.8% had an average time to diagnosis of over 10 years. Therefore, the rising prevalence of hereditary angioedema is driving the growth of the hereditary angioedema market.

Hereditary Angioedema Therapeutics Market Driver: Growth Of The Hereditary Angioedema Therapeutics Market Driven By Increasing Healthcare Expenditure

The increasing healthcare expenditure is expected to boost the growth of the hereditary angioedema therapeutics market going forward. Healthcare expenditure refers to the total amount of resources, including financial resources, spent on healthcare goods and services within a specific period in a given geographical area. Greater healthcare expenditure allows for increased investment in research and development activities focused on understanding the underlying causes of hereditary angioedema and developing innovative therapeutic solutions. For instance, in December 2022, according to the Centers for Medicare & Medicaid Services, a US-based federal agency, U.S. healthcare spending grew by 4.1% to $4.5 trillion in 2022, which is faster than the 3.2% increase in 2021. Therefore, the increasing healthcare expenditure is driving the growth of the hereditary angioedema therapeutics market.

Global Hereditary Angioedema Therapeutics Market Major Players

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Global Hereditary Angioedema Therapeutics Market Trend: Innovative Therapeutic Advancements Shape The Landscape Of Hereditary Angioedema Market

Product innovations are a key trend gaining popularity in the hereditary angioedema therapeutics market. Major companies operating in the hereditary angioedema therapeutics market are developing innovative products such as ligand-conjugated (LICA) investigational antisense medicine and gene therapy to sustain their position in the market. For Instance, in March 2023, Intellia Therapeutics, a US-based clinical-stage biotechnology company, launched an Investigational New Drug (IND) NTLA-2002, which was approved by the United States Food and Drug Administration for the treatment of hereditary angioedema. This enables the company's ongoing Phase 1/2 trial to include the US in the worldwide Phase 2 part. After a single dose of therapy, the inactivation of the target gene, kallikrein B1 (KLKB1), will permanently lower plasma kallikrein protein activity and prevent HAE attacks. NTLA-2002 is a candidate for in vivo genome editing.

Global Hereditary Angioedema Therapeutics Market Trend: Innovative Oral Treatments Transforming Management of Hereditary Angioedema

Major companies operating in the hereditary angioedema (HAE) therapeutics market are developing innovative treatments, such as oral plasma kallikrein inhibitors, to enhance patient management and provide effective, on-demand options for alleviating HAE attacks, thereby improving overall patient outcomes and quality of life. Oral plasma kallikrein inhibitors are drugs taken by mouth that inhibit the enzyme plasma kallikrein, helping to manage and reduce the severity of hereditary angioedema attacks. For instance, in September 2024, KalVista Pharmaceuticals, a US-based biopharmaceutical company, received US. Food and Drug Administration of New drug application for Sebetralstat, aiming to offer HAE patients a more convenient, non-invasive treatment alternative to intravenous or subcutaneous medications. This solution meets the growing demand for fast, effective oral treatments that can be administered immediately during an hereditary angioedema attack.

Hereditary Angioedema Therapeutics Market Merger And Acquisition: Takeda Pharmaceutical Company Acquired Nimbus Lakshmi Inc.

In February 2023, Takeda Pharmaceutical Company, a Japan-based pharmaceutical company, acquired Nimbus Lakshmi Inc. from Nimbus Therapeutics LLC for an undisclosed amount. This acquisition strengthens Takeda's growing late-stage pipeline to expand its portfolio and patient impact across multiple indications and maintains strong global growth over the medium to long term. Nimbus Lakshmi, a fully-owned subsidiary of Nimbus Therapeutics, is a US-based company that provides Tyrosine kinase 2 (TYK2) inhibitor NDI-034858.

Regional Analysis For The Global Hereditary Angioedema Therapeutics Market

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hereditary angioedema therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Hereditary Angioedema Therapeutics Market?

The hereditary angioedema therapeutics market includes revenues earned by entities by diagnosis and evaluation, treatment, and management of hereditary angioedema. The market value includes the value of related goods sold by the service provider or included within the service offering. The hereditary angioedema therapeutics market also includes of sales of tranexamic acid, danazol, intravenous and subcutaneous nano-filtered purified plasma-derived human C1 esterase inhibitor concentrate, and lanadelumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Hereditary Angioedema Therapeutics Industry?

The hereditary angioedema therapeutics market research report is one of a series of new reports from The Business Research Company that provides hereditary angioedema therapeutics market statistics, including hereditary angioedema therapeutics industry global market size, regional shares, competitors with a hereditary angioedema therapeutics market share, detailed hereditary angioedema therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the hereditary angioedema therapeutics industry. This hereditary angioedema therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hereditary Angioedema Therapeutics Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$7.84 billion
Revenue Forecast In 2034	$16.11 billion
Growth Rate	CAGR of 19.7% from 2024 to 2033
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes 2) By Route of Administration: Intravenous, Subcutaneous, Oral 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels 4) By Application: Prophylaxis, On-demand Subsegments: 1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant 2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant 3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab 4) By Other Drug Classes: Emerging Therapies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Hereditary Angioedema Therapeutics Market Characteristics

3. Hereditary Angioedema Therapeutics Market Trends And Strategies

4. Hereditary Angioedema Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Hereditary Angioedema Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Hereditary Angioedema Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Hereditary Angioedema Therapeutics Market Growth Rate Analysis

5.4. Global Hereditary Angioedema Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Hereditary Angioedema Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Hereditary Angioedema Therapeutics Total Addressable Market (TAM)

6. Hereditary Angioedema Therapeutics Market Segmentation

6.1. Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

C1 Esterase Inhibitor

Selective Bradykinin B2 Receptor Antagonist

Kallikrein Inhibitor

Other Drug Classes

6.2. Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous

Subcutaneous

Oral

6.3. Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Other Distribution Channels

6.4. Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Prophylaxis

On-demand

6.5. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plasma-Derived

Recombinant

6.6. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Icatibant

6.7. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Ecallantide

Lanadelumab

6.8. Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Emerging Therapies

7. Hereditary Angioedema Therapeutics Market Regional And Country Analysis

7.1. Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hereditary Angioedema Therapeutics Market

8.1. Asia-Pacific Hereditary Angioedema Therapeutics Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hereditary Angioedema Therapeutics Market

9.1. China Hereditary Angioedema Therapeutics Market Overview

9.2. China Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hereditary Angioedema Therapeutics Market

10.1. India Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hereditary Angioedema Therapeutics Market

11.1. Japan Hereditary Angioedema Therapeutics Market Overview

11.2. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hereditary Angioedema Therapeutics Market

12.1. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hereditary Angioedema Therapeutics Market

13.1. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hereditary Angioedema Therapeutics Market

14.1. South Korea Hereditary Angioedema Therapeutics Market Overview

14.2. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hereditary Angioedema Therapeutics Market

15.1. Western Europe Hereditary Angioedema Therapeutics Market Overview

15.2. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hereditary Angioedema Therapeutics Market

16.1. UK Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hereditary Angioedema Therapeutics Market

17.1. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hereditary Angioedema Therapeutics Market

18.1. France Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hereditary Angioedema Therapeutics Market

19.1. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hereditary Angioedema Therapeutics Market

20.1. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hereditary Angioedema Therapeutics Market

21.1. Eastern Europe Hereditary Angioedema Therapeutics Market Overview

21.2. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hereditary Angioedema Therapeutics Market

22.1. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hereditary Angioedema Therapeutics Market

23.1. North America Hereditary Angioedema Therapeutics Market Overview

23.2. North America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hereditary Angioedema Therapeutics Market

24.1. USA Hereditary Angioedema Therapeutics Market Overview

24.2. USA Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hereditary Angioedema Therapeutics Market

25.1. Canada Hereditary Angioedema Therapeutics Market Overview

25.2. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hereditary Angioedema Therapeutics Market

26.1. South America Hereditary Angioedema Therapeutics Market Overview

26.2. South America Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hereditary Angioedema Therapeutics Market

27.1. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hereditary Angioedema Therapeutics Market

28.1. Middle East Hereditary Angioedema Therapeutics Market Overview

28.2. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hereditary Angioedema Therapeutics Market

29.1. Africa Hereditary Angioedema Therapeutics Market Overview

29.2. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hereditary Angioedema Therapeutics Market Competitive Landscape And Company Profiles

30.1. Hereditary Angioedema Therapeutics Market Competitive Landscape

30.2. Hereditary Angioedema Therapeutics Market Company Profiles

30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Pharming Healthcare Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Attune Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Adverum Biotechnologies Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hereditary Angioedema Therapeutics Market Other Major And Innovative Companies

31.1. Ionis Pharmaceuticals Inc.

31.2. BioCryst Pharmaceuticals Inc.

31.3. CSL Behring LLC

31.4. KalVista Pharmaceutical Inc.

31.5. CENTOGENE N.V.

31.6. GlaxoSmithKline plc.

31.7. Eli Lilly and Company

31.8. Amgen Inc.

31.9. AbbVie Inc.

31.10. Incyte Corporation

31.11. BioMarin Pharmaceutical Inc.

31.12. Dyax Corp.

31.13. Salix Pharmaceuticals Inc.

31.14. Pharvaris N.V.

31.15. Innovent Biologics Inc.

32. Global Hereditary Angioedema Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

34. Recent Developments In The Hereditary Angioedema Therapeutics Market

35. Hereditary Angioedema Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Hereditary Angioedema Therapeutics Market In 2029 - Countries Offering Most New Opportunities

35.2 Hereditary Angioedema Therapeutics Market In 2029 - Segments Offering Most New Opportunities

35.3 Hereditary Angioedema Therapeutics Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Sanofi S.A. Financial Performance

Table 80: Pharming Healthcare Inc. Financial Performance

Table 81: Attune Pharmaceuticals Inc. Financial Performance

Table 82: Adverum Biotechnologies Inc. Financial Performance

Table 83: Arrowhead Pharmaceuticals Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Hereditary Angioedema Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of C1 Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Hereditary Angioedema Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Hereditary Angioedema Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Hereditary Angioedema Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Hereditary Angioedema Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Sanofi S.A. Financial Performance

Figure 80: Pharming Healthcare Inc. Financial Performance

Figure 81: Attune Pharmaceuticals Inc. Financial Performance

Figure 82: Adverum Biotechnologies Inc. Financial Performance

Figure 83: Arrowhead Pharmaceuticals Inc. Financial Performance

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

Global Anticoagulants Market 2022 – Market Opportunities And Strategies

What Is The Compression Therapy Market Overview In 2022?

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth

Cold Pain Therapy Global Market Report 2025 – By Product (OTC Products, Prescription Products), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E- Pharmacies), By Application (Musculoskeletal Disorders, Post-operative Therapy, Sports Injuries, Post-trauma Therapy) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Physical Therapy Software Global Market Report 2025 – By Terminal Type( PC Terminal, Mobile Terminal), By Deployment( On-Premise, Cloud), By Application( Hospitals, Clinics, Others Applications ) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Vitamin D Therapy Global Market Report 2025 – By Administration( Oral, Parenteral), By Purchasing( OTC Drugs, Prescription Drugs), By Age Group( Children, Adults, Senior Adults), By Application( Osteoporosis, Rickets, Skin Diseases, Muscle Weakness, Autoimmune Disorders) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Online Therapy Services Global Market Report 2025 – By Type (Cognitive Behavioral Therapy, Psychodynamic Therapy, Personal Centered Therapy), By Tool (Email, Mobile Device Apps, Real-Time Instant Messaging, Telephone, Video Conferencing), By Application (Residential Use, Commercial) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Targeted Therapy Global Market Report 2025 – By Type (Small Molecule Medicines, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Application (Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Chemotherapy Global Market Report 2025 – By Product Type (Pump, Cannula, Catheter, Other Product Types), By Service (Blood Cancer, Throat Cancer, Lung Cancer, Ovarian Cancer, Stomach Cancer), By Drugs (Alkylating Agents, Antimetabolites, Anti-Tumor Antibiotics, Topoisomerase Inhibitors, Mitotic Inhibitors, Other Drugs), By Route Of Administration (Oral, Intravenous), By End User (Hospitals, Research Institutes, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Testosterone Replacement Therapy Global Market Report 2025 – By Product Type (Oral, Implants, Gel Or Creams, Patches, Buccal Adhesive, Parenteral, Other Products), By Indication (Hypogonadism, Autoimmune Conditions, Genetic Disorders, Sex Organ Surgeries, Other Indications), By Active Ingredient Type (Testosterone, Methyl Testosterone, Testosterone Undecanoate, Testosterone Enanthate, Testosterone Cypionate), By End User (Hospitals, Clinics, Other End-User) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Hormone Therapy Global Market Report 2025 – By Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement), By Route of Administration (Oral, Parenteral, Other Routes of Administration), By Indication (Menopause, Hypothyroidism, Growth Hormone Deficiency, Other Indications), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies And Stores, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Hereditary Angioedema Therapeutics market?

How will the Hereditary Angioedema Therapeutics market drivers and restraints affect the market dynamics? What forces will shape the Hereditary Angioedema Therapeutics industry going forward?

The Hereditary Angioedema Therapeutics market major growth driver - Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market. For further insights on the Hereditary Angioedema Therapeutics market, request a sample here

What is the forecast market size or the forecast market value of the Hereditary Angioedema Therapeutics market?

The Hereditary Angioedema Therapeutics market size has grown strongly in recent years. The hereditary angioedema therapeutics market size has grown rapidly in recent years. It will grow from$6.68 billion in 2024 to $7.84 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to improved diagnosis and awareness, treatment access expansion, research and development initiatives, patient advocacy and education, and regulatory approvals The hereditary angioedema therapeutics market size is expected to see rapid growth in the next few years. It will grow to $16.11 billion in 2029 at a compound annual growth rate (CAGR) of 19.7%. The growth in the forecast period can be attributed to advancements in targeted therapies, global market expansion, gene therapy developments, personalized medicine trends, and collaboration in research and treatment. Major trends in the forecast period include global access initiatives, health economic outcomes research, early intervention strategies, and pediatric HAE therapeutics. For further insights on the Hereditary Angioedema Therapeutics market, request a sample here

How is the Hereditary Angioedema Therapeutics market segmented?

The hereditary angioedema therapeutics market covered in this report is segmented –
1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies For further insights on the Hereditary Angioedema Therapeutics market, request a sample here

Which region has the largest share of the Hereditary Angioedema Therapeutics market? What are the other regions covered in the report?

North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Hereditary Angioedema Therapeutics market, request a sample here.

Who are the major players in the Hereditary Angioedema Therapeutics market?

Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc. . For further insights on the Hereditary Angioedema Therapeutics market, request a sample here.

What are the key trends in the Hereditary Angioedema Therapeutics market?

Major trends in the Hereditary Angioedema Therapeutics market include Innovative Therapeutic Advancements Shape The Landscape Of Hereditary Angioedema Market. For further insights on the Hereditary Angioedema Therapeutics market, request a sample here.

What are the major opportunities in the Hereditary Angioedema Therapeutics market? What are the strategies for the Hereditary Angioedema Therapeutics market?

For detailed insights on the major opportunities and strategies in the Hereditary Angioedema Therapeutics market, request a sample here.

How does the Hereditary Angioedema Therapeutics market relate to the overall economy and other similar markets?

For detailed insights on Hereditary Angioedema Therapeutics's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Hereditary Angioedema Therapeutics industry?

For detailed insights on the mergers and acquisitions in the Hereditary Angioedema Therapeutics industry, request a sample here.

What are the key dynamics influencing the Hereditary Angioedema Therapeutics market growth? SWOT analysis of the Hereditary Angioedema Therapeutics market.

For detailed insights on the key dynamics influencing the Hereditary Angioedema Therapeutics market growth and SWOT analysis of the Hereditary Angioedema Therapeutics industry, request a sample here.